Meeting
2020 Gastrointestinal Cancers Symposium
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.
Authors
Bin Fan
Agios Pharmaceuticals, Inc., Cambridge, MA
Bin Fan , Ghassan K. Abou-Alfa , Andrew X. Zhu , Shuchi Sumant Pandya , Hongxia Jia , Feng Yin , Liewen Jiang , Camelia Gliser , Hua Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02989857
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 539)
Abstract #
539
Poster Bd #
C20
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: Ghassan K. Abou-Alfa
Poster
2017 ASCO Annual Meeting
ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
First Author: Maeve Aine Lowery
Poster
2017 ASCO Annual Meeting
Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
First Author: Maeve Aine Lowery
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world testing, treatment patterns, and outcomes following liquid biopsy in advanced cholangiocarcinoma.
First Author: Amit Mahipal